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Feline coronavirus serotypes 1 and 2: seroprevalence and
association with disease in Switzerland
Abstract
To determine the prevalence of antibodies to feline coronavirus (FCoV) serotypes 1 and 2 in
Switzerland and their association with different disease manifestations, a serological study based on
immunofluorescence tests was conducted with Swiss field cats using transmissible gastroenteritis virus
(TGEV), FCoV type 1 and FCoV type 2 as antigens. A total of 639 serum samples collected in the
context of different studies from naturally infected cats were tested. The current study revealed that,
with an apparent prevalence of 83%, FCoV serotype 1 is the most prevalent serotype in Switzerland.
FCoV type 1 viruses induced higher antibody titers than FCoV type 2, and were more frequently
associated with clinical signs and/or feline infectious peritonitis. The antibody development in seven
cats experimentally infected with FCoV type 1 revealed that, with progressing duration of infection,
antibodies to FCoV type 1 significantly increased over those to FCoV type 2. There was a significant
relationship between antibody titers against TGEV, FCoV 1, and FCoV 2 and TGEV antigen detected
the highest proportion of seropositive cats. We conclude that a vaccine against FCoV should be based
on FCoV type 1-related antigens and that for serodiagnosis of FCoV infection TGEV should be used to
attain the highest diagnostic efficiency. When serology is used in addition to clinical signs, hematology,
and clinical chemistry results as an aid to diagnose clinical FIP, TGEV shows a diagnostic efficiency
equal to that of a FCoV antigen.
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To determine the prevalence of antibodies to feline coronavirus (FCoV) serotypes 1 and 2 in Switzerland and
their association with different disease manifestations, a serological study based on immunofluorescence tests
was conducted with Swiss field cats using transmissible gastroenteritis virus (TGEV), FCoV type 1 and FCoV
type 2 as antigens. A total of 639 serum samples collected in the context of different studies from naturally
infected cats were tested. The current study revealed that, with an apparent prevalence of 83%, FCoV serotype
1 is the most prevalent serotype in Switzerland. FCoV type 1 viruses induced higher antibody titers than FCoV
type 2, and were more frequently associated with clinical signs and/or feline infectious peritonitis. The antibody
development in seven cats experimentally infected with FCoV type 1 revealed that, with progressing duration
of infection, antibodies to FCoV type 1 significantly increased over those to FCoV type 2. There was a significant
relationship between antibody titers against TGEV, FCoV 1, and FCoV 2 and TGEV antigen detected the
highest proportion of seropositive cats. We conclude that a vaccine against FCoV should be based on FCoV type
1-related antigens and that for serodiagnosis of FCoV infection TGEV should be used to attain the highest
diagnostic efficiency. When serology is used in addition to clinical signs, hematology, and clinical chemistry
results as an aid to diagnose clinical FIP, TGEV shows a diagnostic efficiency equal to that of a FCoV antigen.
Intensive research has been done since the first description
of the disease pattern of feline infectious peritonitis (FIP) in
1963 (21), and yet the epidemiology and the pathogenesis of
the fatal disease FIP, which is caused by a coronavirus is still
not fully understood. It was shown that FIP is the single most
important infectious cause of death in young cats, resulting in
the loss of 10% of seropositive kittens during the first year of
life (6).
As for the pathogenesis, it is generally accepted today that
feline coronavirus (FCoV) and FIP-inducing viruses (FIPV)
represent virulence variants of the same virus rather than sep-
arate virus species (39). Most FCoV mutants do not cause
clinical signs, although present at high viral loads; only spo-
radically mutants are pathogenic and induce FIP (28). In some
cases, FCoV infection was found to induce mild enteric symp-
toms (27, 39). It was postulated earlier that harmless FCoVs
were restricted to the intestinal tract and that FIP development
would result from the capability of a virus mutant to induce
systemic infection (33). In the meantime, it was demonstrated
by reverse transcription (RT)-PCR that FCoV generally in-
duces systemic infection (10, 24, 28). Moreover, FCoV and
FIPV have remained serologically and genetically indistin-
guishable.
Antigenetically, coronaviruses are divided into five groups.
Together with canine coronavirus (CCoV) and transmissible
gastroenteritis virus (TGEV), FCoV belongs to group I. Cats
seem susceptible to all group I coronaviruses (23). Some feline
strains are thought to originate from recombinations of FCoV
and other group I viruses, such as CCoV (16).
Based on in vitro neutralization tests, FCoVs were further
classified into two serotypes which differ in their growth char-
acteristics in cell cultures and antigenetic relationship to
TGEV and CCoV; however, both serotypes can cause FIP (7,
32). The serological distinction of FCoV type 1 from type 2 is
most likely associated with differences in the S gene sequence
as monoclonal antibodies to the S protein readily differentiate
the FCoV subtypes (20). Furthermore, FCoV types 1 and 2
have a different cell tropism which can be explained by changes
in the S protein binding to different receptors as demonstrated
previously (18). Cats recovering from FCoV infection develop
especially high titers against the S protein. Many new strains
have recently been isolated (1, 4, 15, 17, 25, 35) and phyloge-
netic examination suggests a spectrum of strains ranging from
very feline-like to more canine-like rather than two distinct
serotypes (1, 4, 25). Whichever system is applied to classify
FCoV, the association between certain FCoV strains and their
ability to induce disease could not yet be elucidated.
Knowledge of the serotype circulating in a given population
is an important prerequisite for the development of a FCoV
vaccine in that the vaccine should be closely related to the field
viruses. The present study was initiated to determine the se-
roprevalence of FCoV types 1 and 2 in Switzerland and find
potential associations between the serotypes and certain dis-
ease manifestations. In addition, we aimed to characterize the
immune response during experimental infection with FCoV 1.
* Corresponding author. Present address: Clinical Laboratory, Uni-
versity of Zurich, Winterthurerstrasse 260, 8057 Zu¨rich, Switzerland.
Phone: 41 (0) 44 635 83 12. Fax: 41 446358906. E-mail: hlutz@vetclinics
.unizh.ch.
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MATERIALS AND METHODS
Cats and serum samples. A total of 667 serum samples collected from natu-
rally and experimentally infected cats during different studies were tested for
FCoV antibodies (Table 1).
The kinetic of antibody development was determined in samples collected
from cats orally infected with FCoV-Rm, a serotype 1 strain (34). Blood had
been taken weekly during the first two months and monthly thereafter up to week
42 after infection (Table 1, group E).
To evaluate the prevalence of FCoV serotype 1 and 2 antibodies, field sera
collected in 1996 and 1997 (9) were used. From this collection, we randomly
selected samples from 296 cats considered healthy by their owners and veteri-
narians (Table 1, group A). To determine the predominant FCoV serotype
present in catteries, samples were used that had been collected in 21 catteries
with different breeds in 2001 and 2002 (14) (Table 1, group B). From each
cattery, three randomly selected samples were pooled because of small sample
volumes.
To investigate a possible relationship between the presence of antibodies to
the two serotypes and clinical signs, samples from the above mentioned 296
healthy cats and 204 clinically ill cats were tested. The latter were presented to
veterinarians with one or more clinical signs of disease including fever, cachexia,
depression, diarrhea, and gastrointestinal tract and/or abdominal problems. The
cats originated from all parts of Switzerland and were of different ages, breeds,
husbandry managements, and sexes (Table 1, group A).
To further characterize the relationship between the presence of antibodies to
one of the FCoV serotypes and FIP, 30 serum samples were evaluated that had
been randomly chosen from a collection of histopathologically confirmed FIP
cases accumulated between 1991 and 1995 (36) (Table 1, group C). For a
reference group, we randomly selected 28 sera collected from diseased cats
without FIP; these serum samples had been stored at the Clinical Laboratory of
the Vetsuisse Faculty, University of Zurich, during the same time period (Table
1, group D).
To determine the immunological relationship between FCoVs 1 and 2 and
TGEV, serum samples of group A were tested for the respective antibodies.
Immunofluorenscence assay (IFA). The FCoV slides and all materials (dilu-
tion and rinse buffer, control sera, and mounting fluid) were kindly donated by
VMRD, Inc. (Pullman, WA). Two different types of slides were used: FCoV type
1 and type 2, grown on Crandell feline kidney cells (CrFK). The positive control
sera had been obtained from ascites of confirmed FIP cases and titrated on both
FCoV 1 and FCoV 2 slides. The negative control sera had been collected from
clinically healthy cats.
Serial dilutions of 1:100, 1:400, 1:1,600, 1:6,400, 1:25,600, 1:102,400, and
1:409,600 were prepared from all samples. The first screening was done at the
dilution of 1:6,400 to avoid false positive results by cross-contamination on the
slides. Endpoint titers were then determined by testing the positive samples at
the higher dilutions whereas the negative samples were further tested at lower
dilutions.
The staining procedure for indirect IFA was performed according to the
manufacturer’s protocol. Briefly, diluted sera were incubated at 37°C for 30 min,
slides were then washed for 10 min before the conjugate (sheep anti-feline
immunoglobulin G [IgG] polyclonal antiserum conjugated to fluorescein isothio-
cyanate) was added for 30 min at again 37°C. After each washing step, the
surfaces of the slides were dried with absorbing paper, preventing the wells from
drying out. Each well contained infected cells (30%) and uninfected cells (70%),
which served as internal negative control.
Serum samples in which antibodies to type 1 were higher than those to type 2
were designated as “antibodies to type 1” and vice versa.
Antibodies to TGEV were tested according to the method of Osterhaus and
Horzinek (30).
Quality control of the FCoV and TGEV slides. To test the 10-well slides for
absence of potential viral contaminants originating from various feline pathogens
handled in our laboratory, cells were removed from the slides by using a sterile
scalpel blade and suspended in 200 l phosphate-buffered saline (PBS). Total
nucleic acids (TNA) were extracted using the MagNA Pure LC total nucleic acid
isolation kit (Roche Diagnostics, Rotkreuz, Switzerland) and eluted in 100 l
elution buffer. The extracts were tested by real-time RT-PCR and PCR for the
following pathogens: FCoV (12), feline leukemia virus (FeLV provirus PCR)
(37), feline immunodeficiency virus (FIV) (26), feline herpes virus 1 (FHV-1)
(40), feline parvovirus (FPV) (28), and feline calicivirus (FCV) (13). FCV was
tested with the following modifications: forward primer, 5-GTT GGA TGA
ACT ACC CGC CAA TC-3; reverse primer, 5-CAT ATG CGG CTC TGA
TGG CTT GAA ACT G-3; and probe, 5-6-carboxyfluorescein (FAM)-TCG
GTG TTT GAT TTG GCC TG-6-carboxytetramethylrhodamine (TAMRA)-3
(C. Helps, personal communication). As uninfected cells present on the slides,
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serving as the internal negative control, did not show any unspecific fluorescence,
the slides were not tested for mycoplasma contamination by PCR.
Molecular characterization of the FCoV 1 and 2 isolates. To further charac-
terize the FCoV strains used for IFA, infected cells were lysed directly on the
slides using 500 l lysis buffer (RLT buffer, RNeasy mini kit; QIAGEN Hom-
brechtikon, Switzerland) and viral RNA was extracted by means of the RNeasy
Mini Kit (QIAGEN). The extracted RNA was checked for FCoV by real-time
RT-PCR (12). A region of about 700 base pairs of the S gene of FCoV was
amplified using the following primer sets: primer set 1 with forward primer
UCD1.3502f (5-GCA CTT AAT GCT TAT GTG TCT CAA A-3) and reverse
primer UCD1.4165r (5-TGA GCC ATT CAA GGT CAA CA-3); primer set 2
with forward primer UCD1.3500f (5-CAG CAC TTA ATG CTT ATG TGT
CTC A-3) and reverse primer UCD1.4173r (5-CAA TCC TGT TGA GCC
ATT CAA G-3); primer set 3 with forward primer FIPV79-1164.3549f (5-AGC
ACT TAA TGC ATT TGT GTC TCA-3) and reverse primer FIPV79-
1164.4230r (5-TTT CAA TTC TAT TGA GCC ATT CAA G-3); primer set 4
with forward primer KU2.3523f (5-GCA CTT AAT GCT TAT GTG TCT C-3)
and reverse primer KU2.4226r (5-CAC ACA TAC CAA GGC C-3); primer set
5 with forward primer KU2.3522f (5-AGC ACT TAA TGC TTA TGT GTC-3)
and reverse primer KU2.4226r (sequence above). Briefly, 2.5 l RNA was am-
plified using the SuperScript III one-step RT-PCR system with Platinum Taq kit
(Invitrogen Life Technologies, Basel, Switzerland), 0.2 M concentrations of
each primer, in a total volume of 25 l. PCR cycling conditions were as follows:
30 min at 50°C (RT step), 2 min at 94°C, 40 cycles of 15 s at 94°C (denaturation),
30 s at 55°C (annealing), and 1 min at 68°C (elongation), followed by 5 min at
68°C.
PCR products from conventional PCR were analyzed on 2% agarose gels;
amplicons were purified using the MinElute gel extraction kit (QIAGEN) and
sequenced from both sides. Cycle sequencing was performed with approximately
20 ng of DNA and 3.3 pmol product-specific primers using the BigDye Termi-
nator Cycle Sequencing Ready Reaction Kit v1.1 (Applied Biosystems, Rot-
kreuz, Switzerland). Cycling conditions were as follows: 1 min at 96°C, then 25
cycles at 96°C for 30 s and 50°C for 15 s, followed by 60°C for 4 min. Products
were purified using the DyeEx Spin column (QIAGEN), and analyzed on the
ABI Prism 310 genetic analyzer (Applied Biosystems). The sequences obtained
from the five primer sets were aligned to one consensus sequence by SeqScape
(version 1.1; Applied Biosystems) and then compared to reference sequences of
the FCoV S gene deposited in the GenBank: KU2 (D32044) and UCD1
(AB088222) for typical type 1 strains and FIPV79-1183 (X80799) and FIPV79-
1164 (X06177) for type 2 strains.
Statistical evaluation. Statistical analyses were performed using StatView 5.1.
(SAS Institute Inc., Cary, NC) and Microsoft Excel. To characterize frequencies
of antibodies to serotypes with respect to significant differences in the different
groups of cats, the 2-test was applied. To evaluate the height of titers in the
different groups of cats, titers were divided into two groups (Table 2). The
association between the nature of symptoms and the serotypes was evaluated by
means of multivariate logistic regression model. To determine the immunolog-
ical relationship between FCoVs 1 and 2 and TGEV, the coefficient of correla-
tion and the regression coefficient using the least square method were applied.
To characterize the kinetic of antibody development for significant differences,
antibody titers were analyzed by analysis of variance (ANOVA), factorial and
repeated measures method, and Fisher’s protected least-significant difference
post hoc test for factorial ANOVA. For the comparison of mean titers, the
Kruskal-Wallis and the Mann-Whitney U test were used. Comparison of groups
was performed by using the 2 test and the post hoc cell contribution as well as
multivariate logistic regression model. P values of 0.05 were considered statis-
tically significant. For the presentations of frequency distributions in Fig. 3 and
4, box plots were used with the upper and lower levels of the boxes representing
the 75th and 25th quartiles, the line in between representing the median and the
whiskers the 2.5th and 97.5th quartile. Outliers are shown as individual dots.
RESULTS
Quality control of the FCoV and TGEV slides. The RT-PCR
and PCR testing for potentially contaminating pathogens
yielded negative results with the exception of FCoV RT-PCR,
which was highly positive (TaqMan cycle threshold values of 18
and 21 for FCoV type 1 and FCoV type 2, respectively, sug-
gesting presence of comparable amounts of viral RNA).
Molecular characterization of the FCoV 1 and 2 isolates.
Partial sequencing of the S gene of FCoV isolated from FIP1
and FIP2 slides (GenBank accession numbers DQ122858 and
DQ122859, respectively) revealed a high homology with pro-
totypes of FCoV type 1 and 2 strains, respectively (Table 3).
Development of antibody titers to FCoV type 1 and 2 during
experimental infection. The course of infection was followed in
seven cats, experimentally infected with a FCoV type 1 strain,
over a period of 40 to 42 weeks (Fig. 1). Antibody titers to type
1 but not type 2 increase significantly after week 17 of the
experiment. Of note, the cats survived the experiment and
showed no clinical signs; the rise of FCoV 1 antibody titers did
not reflect FIP development.
Prevalence of FCoV serotypes in Switzerland. Among 296
clinically healthy cats (group A), 50% were FCoV seropositive.
In 35.1% of the tested animals, titers to FCoV 1 were higher
than those to FCoV 2, while in 4.4% of the cats it was vice
versa, and 10.5% showed identical titers for both FCoV types
(Fig. 2).
There was no statistically significant association between the
husbandry conditions (multicat vs. single cat household) and
FIG. 1. Course of mean titers of antibodies to both FCoV 1 and 2
serotypes in cats experimentally infected with FCoV serotype 1. A
statistically relevant specification of the immune system to the FCoV
serotype of infection can be seen 40/42 weeks after infection (ANOVA
with repeated measures, P  0.038).
TABLE 2. Assignment of titers to two categories
Slide type Low titer High titer
TGEV 1:25–1:400 1:1,600
FCoV 1:100–1:1,600 1:6,400–1:409,600
TABLE 3. Homology of FCoV antigens on IFA slides with FCoV
reference strains
FCoV slide
% Homology
FCoV type 1 strains FCoV type 2 strains
UCD 1 KU2 79–1183 79–1164
FIP 1 91.9 91.8 62.6 61.8
FIP 2 61.8 62.3 94.4 95.3
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the prevalence of FCoV serotypes (2 test, P  0.07). High
titers (1:1,600) to FCoV were more frequently found in cats
from multicat than in single cat households although the dif-
ference was not significant (2 test, P  0.06). Antibodies to
FCoV type 2 had a tendency to be less frequent in multicat
households (2 test, P  0.07).
In 15 (71%) of the 21 Swiss catteries (group B), antibodies
to type 1 were predominant, while in 6 (29%) catteries, anti-
bodies to type 1 and 2 were equal in height. Antibodies to type
2 were predominant in none of the catteries (Fig. 2).
In all cats analyzed, antibody titers against FCoV type 1
were significantly higher than those against FCoV type 2 (Fig.
3).
Association between the FCoV serotype and the clinical
manifestation. Among the 500 field sera from 1996 and 1997
(group A), seropositivity to FCoV (type 1 or type 2) was sig-
nificantly higher in cats with clinical signs than in healthy cats
(2 test, P 0.01). In this association, antibodies to type 1 were
of predominant importance for clinical signs. However, no
statistically significant association was found between the pres-
ence of antibodies to type 1 and any of the six categories of
clinical signs previously found to be associated with possible
FCoV infection (multivariate logistic regression model, P 
0.05).
All of the 30 samples from histopathologically confirmed
FIP cases (group C) were seropositive. In 25 cats (83%), type
1 titers were higher than those to type 2; the remaining 5
animals (17%) had identical titers to both serotypes. In none of
the cats were the titers to type 2 higher than those to type 1
(Fig. 2). In the reference group of non-FIP cases (group D),
43% were seronegative, 50% tested higher for type 1 than for
type 2, 7% showed identical titers to both types, and in no cat
were the titers to type 2 higher than those to type 1 (Fig. 2).
The distribution of titers to the FCoV 1 and 2 serotypes did not
differ significantly between groups A and D (2 test, P  0.2).
Compared to non-FIP cases, the FIP cases had a significantly
higher seroprevalence of FCoV antibodies than any other
group (2 test, P  0.001). In addition, the prevalence of
FIG. 2. Prevalence of FCoV serotypes in different Swiss cat groups. Numbers on bars indicate the percentage of samples within the according
group (A through D) referring to the four categories on the x axis. Categories are defined as follows: neg, antibody titers to both FCoV serotypes
below detectable level; FCoV 1, antibody titers to FCoV 1 greater than antibody titers to FCoV 2; FCoV 2, antibody titers to FCoV 2 greater than
antibody titers to FCoV 1; FCoV 1  FCoV 2, antibody titers to FCoV equal to antibody titers to FCoV 2.
FIG. 3. Box-plot distribution of titers to FCoV types 1 and 2. In
cats with antibodies to FCoV type 1 (1  2), the titers were signifi-
cantly higher than in cats with antibodies to FCoV type 2 (2  1) and
equal titers (1  2; Kruskal-Wallis, P  0.0001).
FIG. 4. Box plot distribution of FCoV (serotype 1 and 2) and
TGEV antibody titers of FIP (group C) and non-FIP cases (group D).
FIP cases show significantly higher FCoV/TGEV antibody titers than
non-FIP cases (Mann-Whitney U test, P  0.0001 for both FCoV and
TGEV). The ratio of median titers of FIP and non-FIP cases was
identical for both FCoV and TGEV antigens.
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antibodies to FCoV 1 was significantly higher in the FIP group
than their reference group D (2 test, P  0.0001).
No association could be detected between the height of titer
and the type of clinical signs (2 test, P  0.2). However, mean
titers to FCoV type 1 in confirmed FIP cases were statistically
higher than titers to FCoV type 1 and 2 in the control group
without FIP (2 test, P  0.0001) (Fig. 4).
Immunological relationship between FCoV type 1 and 2 and
TEGV and diagnostic efficiency. The positive correlation of
titers between FCoVs 1 and 2 (r  0.76, P  0.0001), FCoV
type 1 and TGEV (r 0.46, P 0.0001), and FCoV type 2 and
TGEV (r  0.44, P  0.0001) confirmed the close immuno-
logical relationship of the three antigens tested.
The number of positive IFA results with FCoV 1 was similar
to that obtained with FCoV 2 but lower than using TGEV (Fig.
5). There were 88 samples that tested positive for TGEV but
negative for FCoV; of these samples, 72% had a titer of 25,
27% had a titer of 100, and 1% had a titer of 400. When
serology in addition to the evaluation of clinical parameters,
hematology, and clinical chemistry results was used as an aid to
diagnose clinical FIP, TGEV antigen yielded a diagnostic ef-
ficiency identical to that of both FCoV serotypes (Fig. 4).
DISCUSSION
We have analyzed 667 serum samples from Swiss field cats
and experimentally infected cats for FCoV antibodies by using
FCoV type 1 and type 2 and TGEV slides. We found a prev-
alence of FCoV 1 antibodies (68%) greater than that of FCoV
2 antibodies (9%) while 23% of the cats had equally high titers
to types 1 and 2.
Using molecular assays, we demonstrated that the antigen
preparations were free of contaminating agents including
FeLV, FIV, FHV-1, FPV, and FCV. Based on sequencing
analyses of part of the FCoV S gene, a clear assignment of the
two viruses to prototype FCoV 1 and 2 was possible confirming
the validity of the slides for serodiagnosis of antibodies to
FCoV 1 and 2.
Differentiation of antibodies to type 1 over type 2 occurs late
in experimental FCoV 1 infection. When the antibody devel-
opment to FCoV 1 and 2 was followed in experimentally
FCoV-1-infected cats, it became clear that only after an ob-
servation period of more than 17 weeks antibodies to FCoV 1
showed a significant increase over those to FCoV 2. It suggests
that during the early phase of the infection cross-reacting
epitopes of both types are responsible for comparable titers.
From this experiment we conclude that the B lymphocytes
involved undergo constant stimulation resulting in increasing
concentrations of antibodies and affinity maturation (29) lead-
ing to ever higher antibody specificity to the infecting agent,
i.e., to FCoV 1 over FCoV 2. Hence, a serological differenti-
ation between antibodies to FCoVs 1 and 2 may not be possi-
ble in the early phase of infection but only after the infection
has resulted in an increase of antibody concentration and spec-
ificity.
Prevalence increase of FCoV serotypes in Switzerland. The
prevalence of antibodies to FCoV in the healthy field cats was
found to vary between 14.6% in Japan (19) to70% in Austria
(35). We now report a FCoV seroprevalence of 50% in healthy
Swiss cats; this is more than twofold higher than what we had
found in a study in 1987 (27). Explanations for this increase
include differences in sample selection and/or serologic tests.
While in the earlier study, TGEV slides were used, we now
compared TGEV with FCoV type 1 and 2 slides; all three
antigens gave comparable results. Therefore, the prevalence
increase cannot be attributed to the antigens used. In both
studies, the criteria for sample submission were identical, i.e.,
the veterinarians submitted samples from which they had a
personal interest in obtaining the results. The two studies were
similar with respect to the origin of the samples (single versus
multicat households). Thus, the observed increase may indeed
reflect an increase in seroprevalence between 1987 and 1997.
We found predominantly FCoV type 1 antibodies (68%);
this is in agreement with other serological surveys although the
distribution varies to some degree (1, 19, 32, 35, 38). In parallel
to our experimental study, we hypothesize that serum samples
with antibody titers to FCoV type 1 that are greater than those
to type 2 originate from cats that had been FCoV type 1
infected for more than 17 weeks. Field cats with titers to FCoV
type 1 equal to type 2 (23%) may represent cats infected with
both serotypes or by either virus for a short period. Cats with
titers to FCoV type 2 that were greater than those to type 1
(9%) were considered to be infected by a type 2 virus assuming
that the antibody development after infection with a type 2
FCoV mirrors that of a type 1 infection with specific antibodies
to FCoV type 2 increasing over those to type 1 with time.
Overall, it becomes clear that the true prevalence of type 1 and
2 infection cannot be determined precisely as the status of the
23% of cats displaying identical titers to type 1 and 2 remains
unresolved.
In an earlier report (15), it was stated that cats infected with
FCoV are not readily superinfected by antigenically related
coronaviruses. However, this observation could not be con-
firmed by PCR studies conducted by others (3, 11, 19). Among
the cats with identical titers to both serotypes the majority
(59%) had high titers (1,600). This may reflect coinfection by
both serotypes. Alternatively, it could be explained by an in-
fection caused by a strain not identical but immunologically
equally related to both strains used in the current study. Ad-
ditionally, equal titers to both FCoV types could also be ex-
FIG. 5. Immunological relationship between FCoV types 1 and 2
and TGEV displayed as intersections. Of a total of 500 serum samples,
140 tested negative for coronavirus while the remaining 360 samples
within the circles depicted with broken lines tested positive on at least
one of the three types of immunofluorescence slides. A total of 210
samples tested positive on all three types of test slides, while 88 sam-
ples were detected positive on TGEV slides and 3 on FCoV 1 only.
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plained by antibodies against other structural proteins present
in both viruses, such as the M and N proteins.
Based on the assumption that the virus serotypes within a
cattery cluster around one strain (2, 15, 25), we tested pooled
serum samples of randomly selected Swiss catteries for their
predominant serotype. In none of the catteries antibody titers
to type 2 were predominant. Along with the low seropreva-
lence of type 2 in individual cats, these data support the hy-
pothesis that the type typically known as type 2 does not occur
very frequently in the field. In spite of this, type 2 viruses are
most frequently used in laboratories. This may not reflect their
importance in the field but rather their ease of cultivation in
vitro.
It has been reported that the type 2 FCoV originates from
recombination between coronaviruses of cats and dogs (16).
An association between presence of dogs and serotype 2 FCoV
could not be confirmed due to the retrospective nature of the
study in which no information on the presence of dogs had
been recorded. It could be imagined that some of the type 2
viruses have suboptimal replication activities in vivo which may
explain lower viral loads resulting from infection with these
viruses. This may explain the significantly lower antibody titers
in cats infected with FCoV type 2 compared with those in-
fected with type 1.
The understanding of the mechanisms of the development
of FIP from a FCoV infection is of urgent practical importance
to cat owners in terms of husbandry measures. An association
between multicat environment and height of antibody titers
and the prevalence of FCoV infection was found in our study
confirming other reports (8, 27).
Association between the FCoV serotype and the clinical
manifestation. Antibodies against type 1 are overrepresented
in diseased cats. Additionally, there is a tendency for type 2 to
be less often present, however not at a statistically significant
level. Similarly, in Japan, 80.4% and 10.1% of chronically dis-
eased cats tested positive for FCoV type 1 and type 2, respec-
tively (19). Thus, FCoV type 1 viruses may be more likely to
replicate to high viral load, induce higher antibody titers, and
thereby may become more frequently associated with chronic
disease and/or FIP. Again, this can be explained by the better
adaptation of type 1 to cats. In our study, 100% of confirmed
FIP cases were seropositive to FCoV. This high seroprevalence
in FIP cases was significantly higher than that of the healthy cat
population and corresponds well with 87% and 96% found in
other studies (5, 31). All of our FIP samples tested positive for
type 1 or both types similarly. We could not find a single FIP
case testing higher for type 2. Thus, the above mentioned
hypothesis of FCoV type 1 being of higher pathogenicity than
type 2 appears to be true also for FIP development.
Although confirmed FIP cases showed significantly in-
creased antibody titers to FCoV, no significant association
could be found with height of titers and the category of clinical
signs.
Immunological relationship between FCoV type 1 and 2 and
TEGV and implication for serotesting. The statistically signif-
icant correlation of antibody titers to FCoV 1/FCoV 2, FCoV
1/TGEV, and FCoV 2/TGEV suggest close immunological re-
lationship. From Fig. 5, it becomes evident that TGEV as the
IFA substrate allowed the detection of 88 cats to be seropos-
itive which would not have been detected using FCoV 1 or
FCoV 2 antigens. The low titers of these samples (73% with
titers of 25 and 27% with titers of 100) suggest that TGEV may
be a better substrate, i.e., produces higher concentrations of
viral antigens in its pig cell line than FCoV 1 and 2 grown in cat
cells. Alternatively, the antibodies present in these 88 samples
could have been induced by a third type of FCoV currently not
known which is more closely related to TGEV than FCoV. For
the diagnosis of clinical FIP (36), TGEV is equally suited as
FCoV. Therefore, for FIP diagnosis, either FCoV or TGEV
can be used. It is emphasized, however, that coronavirus titers
alone must not be used as single parameter for FIP diagnosis
(22). However, if seropositivity is to be detected, TGEV in pig
cells appears to be better suited.
In conclusion, it was demonstrated that FCoV type 1 is the
most prevalent FCoV serotype in Switzerland and with this the
distribution is quite similar to that in other parts of the world.
This information may be important for the development of
future FCoV vaccines. Differentiation of the antibody response
to FCoV 1 and 2 does not seem to be very helpful to obtain
information of the disease process in a given cat. However, the
antigens used in this study proved to be highly valuable for the
differentiation of antibodies with specificity for FCoV 1 and 2.
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